Biotech Strategy Blog
Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy
-
What if the first target was the problem?
-
Beyond the Dance: Eric Vivier on rethinking the NK cell paradigm
-
Putting the boat out at ASGCT26
-
Late line RCC: where darlifarnib fits and why LITESPARK-012 matters
-
The goalposts shifted in Berlin, your trial timeline didn’t
-
Pointed ironies: SERD wars, ADC hype, and what really works in breast cancer
-
A study in regulatory conservatism versus clinical innovation
-
What your CD3 T cell engager is missing